Everything below concerns obesity research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-09. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== Mechanism of action == Gliotoxin is suspected to be an important virulence factor (aka pathogenicity factor) in Aspergillus fungus. Gliotoxin possesses immunosuppressive properties that may suppress and cause apoptosis in certain cells of the immune system, including neutrophils, eosinophils, granulocytes, macrophages, and thymocytes. Specifically, neutrophils exposed to gliotoxin release less reactive oxygen species (ROS) and complete fewer phagocytic activities. Gliotoxin is also believed to interfere with T-cell activation. Additionally, gliotoxin acts as an inhibitor of farnesyl transferase. It noncompetitively inhibits the chymotrypsin-like activity of the 20S proteasome. In vivo gliotoxin displays anti-inflammatory activity. It was investigated as an antibiotic and antifungal in the 1940s and as an antiviral agent. Gliotoxin inactivates many different enzymes, including nuclear factor-κB (NF-κB), NADPH oxidase, and glutaredoxin. The inhibition of NF-κB leads prevents cytokine release and induction of the inflammatory response. The immunosuppressive properties of gliotoxin are due to the disulfide bridge within its structure. Interactions occur between sulfur molecules that make up the disulfide bridge and thiol groups contained in cysteine residues. Gliotoxin acts by blocking thiol residues in the cell membrane. Gliotoxin also activates a member of the Bcl-2 family called Bak in order to mediate cell apoptosis. Activated Bak then causes the release of ROS, which form pores within the mitochondrial membrane.
On 10 December 2009, Mgr Yves Le Saux, Bishop of Le Mans, France, opened the diocesan process for the beatification of Zita. Zita was in the habit of spending several months each year in the diocese of Le Mans at St. Cecilia's Abbey, Solesmes, where three of her sisters were nuns. The actor is the French Association pour la Béatification de l'Impératrice Zita. The postulator for the cause is Alexander Leonhardt. Vice postulator for Hungary is Catholic theologian Norbert Nagy. The judge of the tribunal is Bruno Bonnet. The promoter of justice is François Scrive. With the opening of her cause, the late Empress has been named Servant of God.
==== Nonprotein DAMPs ==== Purine metabolites: Nucleotides (e.g., ATP) and nucleosides (e.g., adenosine) that have reached the extracellular space can also serve as danger signals by signaling through purinergic receptors. ATP and adenosine are released in high concentrations after catastrophic disruption of the cell, as occurs in necrotic cell death. Extracellular ATP triggers mast cell degranulation by signaling through P2X7 receptors. Similarly, adenosine triggers degranulation through P1 receptors. Uric acid is also an endogenous danger signal released by injured cells. Adenosine triphosphate (ATP) and uric acid, which are purine metabolites, activate NLR family, pyrin domain containing (NLRP) 3 inflammasomes to induce IL-1β and IL-18.
"Cocaine nose" or "coke nose" are informal terms that refer to nose disorders resulting from repeated or chronic cocaine use. About 30% of people who had snorted cocaine at least 25 times but less than daily, and 47% of daily users, reported experiencing nasal irritation, crusting or scabbing, and frequent nosebleeds. Cocaine use should be considered as a potential cause of persistent or unexplained rhinitis, including in adolescent patients. Because the nose is a prominent facial feature, such visible damage often leads to embarrassment, stigma, and negative reactions from others. As a result, individuals with cocaine-induced nasal damage frequently withdraw from social activities and relationships, leading to social isolation. In many cases, this isolation is not just likely but almost inevitable, as affected individuals may feel unable to face the outside world due to the noticeable and sometimes severe changes to their appearance. Nose disorders associated with cocaine nose include:
Sources: en.wikipedia.org
=== Mechanism of action === Levomethadone (the R-(–)-methadone enantiomer) is a μ-opioid receptor agonist with higher intrinsic activity than morphine, but lower affinity. Dextromethadone (the S-(+)-methadone enantiomer) has a much lower affinity to the μ-opioid receptor than levomethadone. Both enantiomers bind to the glutamatergic NMDA (N-methyl-D-aspartate) receptor, acting as noncompetitive antagonists. Methadone has been shown to reduce neuropathic pain in rat models, primarily through NMDA receptor antagonism. NMDA antagonists such as dextromethorphan, ketamine, tiletamine and ibogaine are being studied for their role in decreasing the development of tolerance to opioids and as possible for eliminating addiction/tolerance/withdrawal, possibly by disrupting memory circuitry. Acting as an NMDA antagonist may be one mechanism by which methadone decreases craving for opioids and tolerance, and has been proposed as a possible mechanism for its distinguished efficacy regarding the treatment of neuropathic pain. Methadone also acted as a potent, noncompetitive α3β4 neuronal nicotinic acetylcholine receptor antagonist in rat receptors, expressed in human embryonic kidney cell lines.
Choose the right targets Continuous research into the pathophysiology of stroke has led to improved ability to select drugs targets. Acute ischemic strokes start when there is reduced blood flow, often caused by an occlusion, to part of the brain. Even if an occlusion causes a complete blockage of a major artery, there is typically still some blood flow downstream of the blockage through collateral blood vessels. With reduced blood flow, there is reduced oxygen supply, and to compensate the tissue goes through anaerobic metabolism which is much less efficient. If anaerobic metabolism does not provide enough energy, there is energy failure, followed by ion imbalances. Afterwards, the pathophysiology gets complicated and there are thought to be at least eight pathways of tissue damage. By targeting processes near the top of the top of the chain of events, problems further down the chain of events can be avoided. For example, the drug tPA and mechanical thrombectomy devices all target the occlusion which is at the top of the chain of events, and have achieved FDA approval. The next step in the chain of events is hypoxia, and some oxygen delivery drugs have shown strong effects in animal studies, as shown in the table below. If processes further down the chain of events get targeted, there may be many simultaneous problems and the effect of a single therapy may be less, so there may be benefit to using multiple drugs in combination to treat multiple pathways.
=== From diet === According to the Asia-Pacific Working Group (APWG) on MASLD, overnutrition is a major factor of MASLD and MASH, particularly for lean MASLD. Diet composition and quantity, in particular omega-6 fatty acid and fructose, have important roles in disease progression from MASL to MASH and fibrosis. Choline deficiency can lead to the development of MASLD. Higher consumption of processed, red, and organ meats have been associated with higher risk of developing MASLD. Some research also suggests eggs are also associated with developing MASLD. On the other hand, studies have found healthful plant foods such as legumes and nuts, to be associated with a lower risk of developing MASLD. Two different studies have found healthy plant-based diets rich in healthy plant foods and low in animal foods to be associated with a lower risk of developing MASLD, even after adjusting for BMI.
=== Definition === The EU defines biopesticides as "a form of pesticide based on micro-organisms or natural products". The US EPA defines biopesticides as “certain types of pesticides derived from such natural materials as animals, plants, bacteria, and certain minerals”. Microorganisms that control pests may also be categorised as biological pest control agents together with larger organisms such as parasitic insects, entomopathic nematodes etc. Natural products may also be categorised as chemical insecticides. The US EPA describes three types of biopesticide. Biochemical pesticides (meaning bio-derived chemicals), which are naturally occurring substances that control pests by non-toxic mechanisms. Microbial pesticides consisting of a microorganism (e.g., a bacterium, fungus, virus or protozoan) as the active ingredient. Plant-Incorporated-Protectants (PIPs) are pesticidal substances that plants produce from genetic material that has been added to the plant (thus producing transgenic crops).
The European Court of Human Rights announces that Ireland launched legal action against the United Kingdom on 17 January over the Northern Ireland Troubles (Legacy and Reconciliation) Act 2023 that gives amnesty to all those accused of killings during the Troubles. 20 January A Royal Navy investigation is launched following a collision between the British warships HMS Chiddingfold and HMS Bangor at a port in Bahrain. A speech to the Fabian Society conference by Shadow Foreign Secretary David Lammy is interrupted by pro-Palestinian protestors. 21 January Weather alerts, including two amber warnings, are issued for the entire UK as Storm Isha brings winds of up to 99 mph. A technical fault prevents some Tesco grocery orders from being fulfilled. A spokesman for Sarah, Duchess of York confirms she has been diagnosed with melanoma following the removal of a cancerous mole during treatment for breast cancer, and is undergoing further investigation. She is the third member of the royal family to undergo a medical procedure in under a week. 22 January Two deaths are reported in the aftermath of Storm Isha, while tens of thousands of homes remain without power, and transport services face ongoing disruption. A new storm – Storm Jocelyn – is expected to hit parts of the UK tomorrow. After the Royal Mail proposes that its deliveries should be made from Monday to Friday only, Downing Street states that the government would not support such a move, with the Prime Minister expressing a view that Saturday deliveries provide "flexibility and convenience".
Sources: en.wikipedia.org
Wild arapaima are harpooned or caught in large nets. Since the arapaima needs to surface to breathe air, traditional arapaima fishermen harpoon them and then club them to death. An individual fish can yield as much as 70 kg (150 lb) of meat. The arapaima was introduced for fishing in Thailand and Malaysia. Fishing in Thailand can be done in several lakes, where specimens over 150 kg (330 lb) are often landed and then released. On 14 May 2020, a 30 kg (66 lb) specimen was found floating in the river in Angkor Wat area, Krovanh village, Sangkat Norkor Thom, Siem Reap, Cambodia; the locals said it was a rare fish, and not commonly seen in this area. With catch-and-release after the fish is landed, it must be held for 5 minutes until it takes a breath. The fish has a large blood vessel running down its spine, so lifting the fish clear of the water for trophy shots can rupture this vessel, causing death.
Internalizing RGD (iRGD) peptides are a class of 9-amino acid cyclic peptides containing an RGD sequence, which undergo internalization as discussed below. The prototypic iRGD peptide, shown in the image on the right (sequence: CRGDKGPDC; CAS 1392278-76-0), was originally identified in an in vivo screening of phage display libraries in tumor-bearing mice. The peptide was able to home to tumor tissues, but in contrast to standard RGD (arginylglycylaspartic acid) peptides, spread much more extensively into extravascular tumor tissue. It was later identified that this extravasation and transport through extravascular tumor tissue is due to the bifunctional action of the molecule: after the initial RGD-mediated tumor homing, another pharmacologic motif is able to manipulate tumor microenvironment, making it temporarily accessible to circulating drugs. This second step is mediated through specific secondary binding to neuropilin-1 receptor, and subsequent activation of a trans-tissue pathway, dubbed the C-end Rule, or CendR pathway.
hybridization probe A single-stranded DNA or RNA fragment (or a nucleic acid analogue) which is artificially labelled with a radioactive or fluorescent compound or some other detectable marker and then allowed to hybridize with complementary DNA or RNA sequences in order to detect the presence of those complements in a heterogeneous sample or their specific in situ localization; or an assay in which this procedure is performed. As with antibodies in immunostaining, nucleic acid probes bind with high specificity to their target sequences, permitting visualization of the targets, if present, against a non-specific background, whether in a membrane blot or microarray or even in vivo. A unique advantage of hybridization probes is that the stringency of the hybridization reaction is easily modifiable by changing the temperature and salt concentration, making it possible for the same probe to bind to sequences with differing degrees of complementarity. Hybridization probes are employed in Southern blotting and northern blotting and as part of many other laboratory methods. See also probe.
de Lorenzo, Victor; Schmidt, Markus (April 2016). "Synthetic bugs on the loose: containment options for deeply engineered (micro)organisms". Current Opinion in Biotechnology. 38: 90–96. doi:10.1016/j.copbio.2016.01.006. PMID 26874261.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.